Clinical Utility of the 70-gene MammaPrint Profile in a Japanese Population

Publication Name: Japanese Journal of Clinical Oncology

Author(s): Makoto Ishitobi, Teodora Goranova, Yoshifumi Komoike, Kazuyoshi Motomura, Hiroki Koyama, Annuska Glas, Ellen van Lienen, Hideo Inaji Laura van’t Veer and Kikuya Kato

Objective: van’t Veer and colleagues developed a 70-gene prognosis profile known as MammaPrint to identify breast cancer patients who were at low risk of developing metastases. We evaluated the prognostic value of the 70-gene MammaPrint profile in Japanese women with … Continued

MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer.

Publication Name: Expert Opinion Medical Diagnostics

Author(s): Phillipe L Bedard, Stella Mook, Martine J Piccart-Gebhart, Emiel T Rutgers, Laura J van ‘t Veer and Fatima Cardoso

Background: Over the past few years, a variety of multigene expression profiles have been developed to improve prognostication for early stage breast cancer and reduce overtreatment with chemotherapy. MammaPrint is the only test cleared by the US Food and Drug … Continued

Validation of 70-gene prognosis signature in node-negative breast cancer

Publication Name: Breast Cancer Research & Treatment

Author(s): Bueno-de-Mesquita JM, Keijzer R, Linn SC

Purpose: The 70-gene prognosis signature (van’t Veer et al., Nature 415(6871):530–536, 2002) may improve the selection of lymph node-negative breast cancer patients for adjuvant systemic therapy. Optimal validation of prognostic classifiers is of great importance and we therefore wished to … Continued

Use of a 70-Gene Signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

Publication Name: Lancet Oncology

Author(s): Jolien M Bueno-de-Mesquita MD, Prof Wim H van Harten MD, Valesca P Retel MSc, Laura J van 't Veer PhD, Prof Frits SAM van Dam PhD, Kim Karsenberg MSc, Kirsten FL Douma MSc, Harm van Tinteren PhD, Johannes L Peterse MD, Jelle Wesseling MD, Tin S Wu MSc, Douwe Atsma BSc, Prof Emiel JT Rutgers MD, Guido Brink BSc, Arno N Floore BSc, Annuska M Glas PhD, Rudi MH Roumen MD, Frank E Bellot MD, Cees van Krimpen MD, Prof Sjoerd Rodenhuis MD, Prof Marc J van de Vijver MD, Dr Sabine C Linn MD

Background: A microarray-based 70-gene prognosis signature [MammaPrint] might improve the selection of patients with node-negative breast cancer for adjuvant systemic treatment. The main aims of this MicroarRAy PrognoSTics in Breast CancER (RASTER) study were to assess prospectively the feasibility of … Continued